Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$3.17
-3.4%
$3.32
$2.71
$4.73
$607.14M1.2956,829 shs1.12 million shs
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
$32.48
$32.44
$7.26
$32.50
$3.73B0.324.11 million shs73 shs
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$0.53
$0.53
$0.53
$7.77
$1.56M1.1893,010 shsN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$2.32
-1.7%
$1.86
$1.07
$4.62
$244.09M0.36661,984 shs186,473 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.00%-2.01%-11.45%+0.96%-7.04%
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
0.00%0.00%0.00%0.00%0.00%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
0.00%0.00%0.00%0.00%-92.81%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
0.00%+8.26%+19.59%+107.14%+35.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
2.1391 of 5 stars
3.50.00.00.02.72.50.6
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
2.5398 of 5 stars
3.65.00.00.02.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5073.50% Upside
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
0.00
N/AN/AN/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
2.25
Hold$10.001,798.97% Upside
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
3.13
Buy$8.00244.83% Upside

Current Analyst Ratings Breakdown

Latest ABUS, CBAY, ONCT, and PRQR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$8.00
6/27/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$8.00
5/13/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.00
4/29/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$8.00
4/29/2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
$6.40M94.82N/AN/A$0.51 per share6.22
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
$31.07M119.92N/AN/A$2.58 per share12.59
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
$790K1.97N/AN/A$10.19 per share0.05
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
$18.97M12.86N/AN/A$0.91 per share2.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)

Latest ABUS, CBAY, ONCT, and PRQR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.02N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/8/2025Q1 2025
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
N/AN/AN/AN/AN/A
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/AN/AN/AN/AN/A
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
0.04
6.01
6.01
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
N/A
10.96
10.96
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
N/A
2.39
2.39
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
N/A
4.10
4.10

Institutional Ownership

CompanyInstitutional Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
43.79%
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
95.03%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
16.05%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
32.65%

Insider Ownership

CompanyInsider Ownership
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
20.30%
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
7.00%
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
11.20%
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arbutus Biopharma Corporation stock logo
ABUS
Arbutus Biopharma
90191.53 million152.65 millionOptionable
CymaBay Therapeutics, Inc. stock logo
CBAY
CymaBay Therapeutics
101114.72 million106.69 millionOptionable
Oncternal Therapeutics, Inc. stock logo
ONCT
Oncternal Therapeutics
302.96 million2.63 millionNo Data
ProQR Therapeutics N.V. stock logo
PRQR
ProQR Therapeutics
180105.21 million96.38 millionOptionable

Recent News About These Companies

ProQR Therapeutics N.V. (PRQR) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.17 -0.11 (-3.35%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.14 -0.03 (-0.95%)
As of 07/11/2025 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

CymaBay Therapeutics stock logo

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Oncternal Therapeutics stock logo

Oncternal Therapeutics NASDAQ:ONCT

$0.53 0.00 (0.00%)
As of 04/29/2025

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.

ProQR Therapeutics stock logo

ProQR Therapeutics NASDAQ:PRQR

$2.32 -0.04 (-1.69%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.42 +0.10 (+4.31%)
As of 07/11/2025 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.